{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:00:50Z","timestamp":1790938850037,"version":"4.1.0"},"reference-count":25,"publisher":"Becaris Publishing Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Alagille syndrome (ALGS) is a rare genetic disorder associated with cholestasis and subsequent severe pruritus, which significantly impacts patient quality of life (QoL). Odevixibat (ODX) and maralixibat (MRX) are ileal bile acid transporter inhibitors approved for the treatment of cholestatic pruritus in ALGS. In the absence of head-to-head data, this study aimed to compare the efficacy, safety, and health-related QoL (HRQoL) associated with ODX and MRX.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A population-adjusted unanchored indirect treatment comparison was conducted using patient-level data from the Phase III ASSERT\/ASSERT-EXT studies (ODX) and published data from the Phase IIb ICONIC study (MRX). A regression-adjusted matching approach was applied to adjust for cross-trial differences in baseline characteristics and estimate treatment effects. Outcomes assessed at week 48 included pruritus, serum bile acid (sBA) levels, HRQoL (PedsQL) and safety.\n                    <jats:bold>Results:<\/jats:bold>\n                    In adjusted analyses, ODX demonstrated numerically greater improvements in pruritus and reductions in sBA than MRX. ODX was associated with significantly greater improvements in HRQoL, including overall PedsQL scores (mean difference: 14.64; 95% CI: 5.70\u201323.58). ODX was better tolerated, with significantly lower rates of gastrointestinal adverse events (odds ratio [OR]: 0.22; 95% CI: 0.06\u20130.87) and abdominal pain (OR: 0.06; 95% CI: 0\u20130.83), and numerically lower rates of other adverse events.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In this first indirect treatment comparison of ileal bile acid transporter inhibitors in ALGS, ODX demonstrated a differentiated clinical profile versus MRX, with significant benefits in HRQoL and tolerability, and consistent trends favoring better efficacy. These results may support informed treatment decision-making for patients.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0138","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:49:24Z","timestamp":1789721364000},"source":"Crossref","is-referenced-by-count":0,"title":["Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-0465","authenticated-orcid":false,"given":"Emmanuelle","family":"Kaltenbach","sequence":"first","affiliation":[{"name":"Ipsen, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Guiraud-Diawara","sequence":"additional","affiliation":[{"name":"Ipsen, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Schwarzbard","sequence":"additional","affiliation":[{"name":"Ipsen, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Artaud","sequence":"additional","affiliation":[{"name":"Ipsen, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2013.140","article-title":"Clinical utility gene card for: Alagille syndrome (ALGS)","volume":"22","author":"Leonard LD","year":"2014","unstructured":"Leonard LD, Chao G, Baker A, Loomes K, Spinner NB. Clinical utility gene card for: Alagille syndrome (ALGS). Eur. J. Hum. Genet. 22(3), doi: 10.1038\/ejhg.2013.140 (2014) (Epub ahead of print).","journal-title":"Eur. J. Hum. Genet."},{"issue":"12","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/humu.23879","article-title":"Alagille syndrome mutation update: comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification","volume":"40","author":"Gilbert MA","year":"2019","unstructured":"Gilbert MA, Bauer RC, Rajagopalan R Alagille syndrome mutation update: comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. Hum. Mutat. 40(12), 2197\u20132220 (2019).","journal-title":"Hum. Mutat."},{"issue":"2","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.32761","article-title":"Natural history of liver disease in a large international cohort of children with Alagille syndrome: results from the GALA study","volume":"77","author":"Vandriel SM","year":"2023","unstructured":"Vandriel SM, Li LT, She H Natural history of liver disease in a large international cohort of children with Alagille syndrome: results from the GALA study. Hepatology 77(2), 512\u2013529 (2023).","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40271-017-0266-4","article-title":"Development of a novel tool to assess the impact of itching in pediatric cholestasis","volume":"11","author":"Kamath BM","year":"2018","unstructured":"Kamath BM, Abetz-Webb L, Kennedy C Development of a novel tool to assess the impact of itching in pediatric cholestasis. Patient 11(1), 69\u201382 (2018).","journal-title":"Patient"},{"issue":"2","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/MPG.0000000000001958","article-title":"Systematic review: the epidemiology, natural history, and burden of Alagille syndrome","volume":"67","author":"Kamath BM","year":"2018","unstructured":"Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic review: the epidemiology, natural history, and burden of Alagille syndrome. J. Pediatr. Gastroenterol. Nutr. 67(2), 148\u2013156 (2018).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"8","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/lt.23437","article-title":"Outcomes of liver transplantation for patients with Alagille syndrome: the studies of pediatric liver transplantation experience","volume":"18","author":"Kamath BM","year":"2012","unstructured":"Kamath BM, Yin W, Miller H Outcomes of liver transplantation for patients with Alagille syndrome: the studies of pediatric liver transplantation experience. Liver Transpl. 18(8), 940\u2013948 (2012).","journal-title":"Liver Transpl."},{"issue":"2","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jhep.2024.04.006","article-title":"EASL Clinical Practice Guidelines on genetic cholestatic liver diseases","volume":"81","author":"EASL","year":"2024","unstructured":"EASL. EASL Clinical Practice Guidelines on genetic cholestatic liver diseases. J. Hepatol. 81(2), 303\u2013325 (2024).","journal-title":"J. Hepatol."},{"issue":"36","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"33920","DOI":"10.1074\/jbc.M306370200","article-title":"Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice","volume":"278","author":"Dawson PA","year":"2003","unstructured":"Dawson PA, Haywood J, Craddock AL Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. 278(36), 33920\u201333927 (2003).","journal-title":"J. Biol. Chem."},{"key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"110835","DOI":"10.1016\/j.biopha.2020.110835","article-title":"ASBT(SLC10A2): a promising target for treatment of diseases and drug discovery","volume":"132","author":"Yang N","year":"2020","unstructured":"Yang N, Dong YQ, Jia GX ASBT(SLC10A2): a promising target for treatment of diseases and drug discovery. Biomed. Pharmacother. 132, 110835 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"e_1_3_8_12_2","volume-title":"Prescribing Information","author":"Bylvay","year":"2025","unstructured":"Bylvay. Prescribing Information. Ipsen Biopharmaceuticals, Inc, MA, USA (2025)."},{"key":"e_1_3_8_13_2","volume-title":"Summary of Product Characteristics","author":"Kayfanda","year":"2025","unstructured":"Kayfanda. Summary of Product Characteristics. Ipsen Pharma, France (2025)."},{"issue":"7","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a Phase III, double-blind, randomised, placebo-controlled trial","volume":"9","author":"Ovchinsky N","year":"2024","unstructured":"Ovchinsky N, Aumar M, Baker A Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a Phase III, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol. Hepatol. 9(7), 632\u2013645 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"e_1_3_8_15_2","volume-title":"The 75th AmeriCAn Association for the Study of Liver Disease Annual Meeting","author":"Ovchinsky N","year":"2024","unstructured":"Ovchinsky N, Aumar M, Baker A ASSERT-EXT: final data from an open-label, Phase III study of odevixibat in patients with Alagille syndrome. Presented at: The 75th AmeriCAn Association for the Study of Liver Disease Annual Meeting, CA, USA (15\u201319 November 2024)."},{"key":"e_1_3_8_16_2","volume-title":"Prescribing Information","author":"Livmarli","year":"2025","unstructured":"Livmarli. Prescribing Information. Mirum Pharmaceuticals, Inc, CA, USA (2025)."},{"key":"e_1_3_8_17_2","volume-title":"Summary of Product Characteristics","author":"Livmarli","year":"2025","unstructured":"Livmarli. Summary of Product Characteristics. Mirum Pharmaceuticals International B.V, The Netherlands (2025)."},{"issue":"10311","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised Phase II study","volume":"398","author":"Gonzales E","year":"2021","unstructured":"Gonzales E, Hardikar W, Stormon M Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised Phase II study. Lancet 398(10311), 1581\u20131592 (2021).","journal-title":"Lancet"},{"issue":"2","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s10742-013-0109-2","article-title":"Regression-adjusted matching and double-robust methods for estimating average treatment effects in health economic evaluation","volume":"13","author":"Kreif N","year":"2013","unstructured":"Kreif N, Grieve R, Radice R, Sekhon JS. Regression-adjusted matching and double-robust methods for estimating average treatment effects in health economic evaluation. Health Serv. Outcomes Res. Methodol. 13(2), 174\u2013202 (2013).","journal-title":"Health Serv. Outcomes Res. Methodol."},{"key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpeds.2022.09.001","article-title":"Maralixibat treatment response in Alagille syndrome is associated with improved health-related quality of life","volume":"252","author":"Kamath BM","year":"2023","unstructured":"Kamath BM, Goldstein A, Howard R Maralixibat treatment response in Alagille syndrome is associated with improved health-related quality of life. J. Pediatr. 252, 68\u201375; e65 (2023).","journal-title":"J. Pediatr."},{"key":"e_1_3_8_21_2","volume-title":"NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE","author":"Phillippo DM","year":"2016","unstructured":"Phillippo DM, Ades T, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. NICE, UK (2016)."},{"key":"e_1_3_8_22_2","unstructured":"Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons. Member State Coordination Group on Health Technology Assessment (2024) (Accessed September 2026). Available at: https:\/\/health.ec.europa.eu\/document\/download\/1f6b8a70-5ce0-404e-9066-120dc9a8df75_en?filename=hta_practical-guideline_direct-and-indirect-comparisons_en.pdf."},{"key":"e_1_3_8_23_2","volume-title":"The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Congress","author":"Sturm E","year":"2025","unstructured":"Sturm E, Aumar M, Baker A Long-term efficacy and safety of odevixibat in patients with Alagille syndrome: pooled results from Phase III, randomized, double-blind ASSERT and open-label ASSERT-EXT studies. Presented at: The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Congress, Helsinki, Finland (2025)."},{"issue":"6","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"102508","DOI":"10.1016\/j.isci.2021.102508","article-title":"Microbiome-encoded bile acid metabolism modulates colonic transit times","volume":"24","author":"Li N","year":"2021","unstructured":"Li N, Koester ST, Lachance DM, Dutta M, Cui JY, Dey N. Microbiome-encoded bile acid metabolism modulates colonic transit times. iScience 24(6), 102508 (2021).","journal-title":"iScience"},{"issue":"1","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2012.09.055","article-title":"The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice","volume":"144","author":"Alemi F","year":"2013","unstructured":"Alemi F, Poole DP, Chiu J The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144(1), 145\u2013154 (2013).","journal-title":"Gastroenterology"},{"issue":"4","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/HEP.0000000000001430","article-title":"Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiency","volume":"83","author":"Nomden M","year":"2026","unstructured":"Nomden M, Kuipers F, Lexmond WS Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiency. Hepatology 83(4), 708\u2013720 (2026).","journal-title":"Hepatology"},{"issue":"10","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/metabo12100952","article-title":"Serum bile acid profiling and mixed model analysis reveal biomarkers associated with pruritus reduction in maralixibat-treated patients with BSEP deficiency","volume":"12","author":"Zhao X","year":"2022","unstructured":"Zhao X, Zhang W, Vig P, Kostrub C, Setchell KDR. Serum bile acid profiling and mixed model analysis reveal biomarkers associated with pruritus reduction in maralixibat-treated patients with BSEP deficiency. Metabolites 12(10), 952 (2022).","journal-title":"Metabolites"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:43:55Z","timestamp":1790937835000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.57264\/cer-2026-0138"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0138","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"article-number":"e260138"}}